Total Versus Partial Omentectomy in the Treatment of Gastric Cancer (TOPO)
Primary Purpose
Stomach Neoplasms, Interleukin, Stomach Cancer
Status
Recruiting
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Partial omentectomy
Sponsored by
About this trial
This is an interventional treatment trial for Stomach Neoplasms focused on measuring gastric cancer, total omentectomy, partial omentectomy, stomach cancer, interleukin, immunological answer
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) I-III., Karnofsky Performance Score (KPS) >60, Eastern Cooperative Oncology Group (ECOG) 0-1
- Tis-T3 gastric cancer without serosal infiltration and treated with the radical operation (R0; D2 lymphadenectomy, lymph nodes >16)
- clinical stadium: Tis-3; M0
- written informed consent provided
- good patient compliance
- no previous chemotherapy or irradiation
Exclusion Criteria:
- serosal infiltration and/or distant metastasis, omental infiltration, peritoneal carcinosis, positive abdominal cytological lavage
- organ transplantation and/or immunological disease and/or immunomodulation therapy
- another primary tumor
- decompensated chronic disease (for example: liver cirrhosis with ascites, kidney failure treated with hemodialysis, New York Heart Association (NYHA) IV. cardiac status, etc.)
- unsuccessful follow-up
Sites / Locations
- University of Debrecen - Surgical ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Total omentectomy
Partial omentectomy
Arm Description
Total or subtotal gastrectomy with D2 lymphadenectomy and total omentectomy.
Total or subtotal gastrectomy with D2 lymphadenectomy and partial omentectomy.
Outcomes
Primary Outcome Measures
3y Overall Surveillance
Duration from the operation to the date of death.
3y Disease Free Surveillance
Duration from the operation to the date of radiological or histological proven relapse.
Secondary Outcome Measures
Postoperative Complications (Clavien - Dindo classification) and morbidity
Incidence of 30 days postoperative morbidity (Clavien - Dindo classification).
Postoperative immunological changes (Interleukin monitoring)
Compare the pre-and postoperative interleukin blood levels to monitoring the immunological answer after total or partial omentectomy.
Full Information
NCT ID
NCT05238584
First Posted
February 3, 2022
Last Updated
May 16, 2022
Sponsor
University of Debrecen
Collaborators
National Institute of Oncology, Hungary, University of Pecs, Uzsoki Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05238584
Brief Title
Total Versus Partial Omentectomy in the Treatment of Gastric Cancer
Acronym
TOPO
Official Title
A Multicenter, Prospective, Randomized Trial to Evaluate the Role of Total Versus Partial Omentectomy in the Treatment of Tis - T3 Gastric Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
July 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Debrecen
Collaborators
National Institute of Oncology, Hungary, University of Pecs, Uzsoki Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main purpose of this study is to evaluate the role of the type of omentectomy (partial or total) in the treatment of Tis - T3 gastric cancer without serosal infiltration. The second purpose is to monitoring the blood levels of immunological factors (interleukins, T cell subtypes, etc.) pre-and postoperatively, depending on the type of omentectomy.
Detailed Description
Gastric cancer is the second common tumor type. In 2020, the incidence of gastric cancer was over one million and caused about 770 000 tumor-associated deaths worldwide. Although the improvement of the perioperative oncological therapy is unquestionable, the major point of the treatment is radical surgical intervention. Laparoscopic technic is widespread in the treatment of gastric cancer, too. For the oncological radicality total or subtotal gastrectomy with D2 omentectomy is necessary, but the opinions are divided about the role of the omentectomy. Total omentectomy in laparoscopic operations takes more time and increases the postoperative morbidity, blood loss, and opportunity of the anastomosis insufficiency, and the incidence of the omental metastases is just between 3,8 - 5%. Based on this, many international guidelines allow partial omentectomy in early gastric cancer. At the same time, in advanced gastric neoplasm, the place of the partial omentectomy is still unclear.
With this prospective, randomized, multicentric study we plan to compare the total and partial omentectomy in the surgery of Tis - T3 gastric cancer with the analysis of the postoperative morbidity and mortality and long-term survival factors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stomach Neoplasms, Interleukin, Stomach Cancer, Gastric Cancer, Digestive System Neoplasm
Keywords
gastric cancer, total omentectomy, partial omentectomy, stomach cancer, interleukin, immunological answer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Total omentectomy
Arm Type
No Intervention
Arm Description
Total or subtotal gastrectomy with D2 lymphadenectomy and total omentectomy.
Arm Title
Partial omentectomy
Arm Type
Experimental
Arm Description
Total or subtotal gastrectomy with D2 lymphadenectomy and partial omentectomy.
Intervention Type
Procedure
Intervention Name(s)
Partial omentectomy
Intervention Description
Partial omentectomy: with preservation of the greater omentum at >2 cm from the gastroepiploic arcade.
Primary Outcome Measure Information:
Title
3y Overall Surveillance
Description
Duration from the operation to the date of death.
Time Frame
3 years
Title
3y Disease Free Surveillance
Description
Duration from the operation to the date of radiological or histological proven relapse.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Postoperative Complications (Clavien - Dindo classification) and morbidity
Description
Incidence of 30 days postoperative morbidity (Clavien - Dindo classification).
Time Frame
30 days
Title
Postoperative immunological changes (Interleukin monitoring)
Description
Compare the pre-and postoperative interleukin blood levels to monitoring the immunological answer after total or partial omentectomy.
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
Patient Data
Description
Patient age, sex, BMI, etc.
Time Frame
1 week
Title
Surgical Data
Description
Duration of the operation, type of the operation (laparoscopic or open), intraoperative blood loss, etc.
Time Frame
1 week
Title
Histopathological Data
Description
Type of the tumor, TNM stadium, positive resection border, etc.
Time Frame
1 month
Title
Duration of the hospital stay
Description
The time from the date of operation to the date of discharge.
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists (ASA) I-III., Karnofsky Performance Score (KPS) >60, Eastern Cooperative Oncology Group (ECOG) 0-1
Tis-T3 gastric cancer without serosal infiltration and treated with the radical operation (R0; D2 lymphadenectomy, lymph nodes >16)
clinical stadium: Tis-3; M0
written informed consent provided
good patient compliance
no previous chemotherapy or irradiation
Exclusion Criteria:
serosal infiltration and/or distant metastasis, omental infiltration, peritoneal carcinosis, positive abdominal cytological lavage
organ transplantation and/or immunological disease and/or immunomodulation therapy
another primary tumor
decompensated chronic disease (for example: liver cirrhosis with ascites, kidney failure treated with hemodialysis, New York Heart Association (NYHA) IV. cardiac status, etc.)
unsuccessful follow-up
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dezső Tóth
Phone
+36 (52) 411 - 717
Ext
55316
Email
dr.toth.dezso@med.unideb.hu
First Name & Middle Initial & Last Name or Official Title & Degree
Péter Kolozsi
Phone
+36 (52) 411 - 717
Ext
55423
Email
kolozsi.peter@med.unideb.hu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dezső Tóth
Organizational Affiliation
University of Debrecen - Surgical Clinic
Official's Role
Study Chair
Facility Information:
Facility Name
University of Debrecen - Surgical Clinic
City
Debrecen
State/Province
Hajdú - Bihar
ZIP/Postal Code
4033
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dezső Tóth
Phone
+36 (52) 411 - 717
Ext
55316
Email
dr.toth.dezso@med.unideb.hu
Phone
+36 (52) 411 - 717
Ext
55423
Email
kolozsi.peter@med.unideb.hu
First Name & Middle Initial & Last Name & Degree
Dezső Tóth
First Name & Middle Initial & Last Name & Degree
Péter Kolozsi
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22207307
Citation
Hamabe A, Omori T, Tanaka K, Nishida T. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc. 2012 Jun;26(6):1702-9. doi: 10.1007/s00464-011-2096-0. Epub 2011 Dec 30.
Results Reference
background
PubMed Identifier
31987046
Citation
Zeng F, Chen L, Liao M, Chen B, Long J, Wu W, Deng G. Laparoscopic versus open gastrectomy for gastric cancer. World J Surg Oncol. 2020 Jan 27;18(1):20. doi: 10.1186/s12957-020-1795-1.
Results Reference
background
PubMed Identifier
18536863
Citation
Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Omentum-preserving gastrectomy for early gastric cancer. World J Surg. 2008 Aug;32(8):1703-8. doi: 10.1007/s00268-008-9598-5.
Results Reference
background
PubMed Identifier
22028160
Citation
Kim MC, Kim KH, Jung GJ, Rattner DW. Comparative study of complete and partial omentectomy in radical subtotal gastrectomy for early gastric cancer. Yonsei Med J. 2011 Nov;52(6):961-6. doi: 10.3349/ymj.2011.52.6.961.
Results Reference
background
PubMed Identifier
27550526
Citation
Jongerius EJ, Boerma D, Seldenrijk KA, Meijer SL, Scheepers JJ, Smedts F, Lagarde SM, Balague Ponz O, van Berge Henegouwen MI, van Sandick JW, Gisbertz SS. Role of omentectomy as part of radical surgery for gastric cancer. Br J Surg. 2016 Oct;103(11):1497-503. doi: 10.1002/bjs.10149. Epub 2016 Aug 23.
Results Reference
background
PubMed Identifier
24669875
Citation
Kim DJ, Lee JH, Kim W. A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomy. World J Surg Oncol. 2014 Mar 26;12:64. doi: 10.1186/1477-7819-12-64.
Results Reference
background
PubMed Identifier
32060757
Citation
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan;24(1):1-21. doi: 10.1007/s10120-020-01042-y. Epub 2020 Feb 14. No abstract available.
Results Reference
background
Links:
URL
https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
Description
World Health Organisation (WHO) International Agency for Research on Cancer - Stomach
Learn more about this trial
Total Versus Partial Omentectomy in the Treatment of Gastric Cancer
We'll reach out to this number within 24 hrs